1.Prokaryotic expression of HLA-B * 2705 heavy chain and identification for its activity.
Yan-Bo LI ; Yu-Ying SUN ; Si-Qi GUO ; Ye-Ping SUN ; Xiu-Yun ZHANG ; Fan-Hua KONG ; Yong-Zhi XI
Journal of Experimental Hematology 2007;15(5):1028-1031
In order to investigate the expression of heavy chain of HLA-B * 2705 in prokaryotic system and identify its activity, the extra-membrane gene fragment of HLA-B * 2705 was amplified from full-length HLA-B*2705 cDNA by PCR and cloned into pGEM-T vector. After identification by sequencing, the prokaryotic expressing vector pET32a (+)-B * 2705 was constructed. The antigenic activity of expressed protein was identified by Western blot and antibody blocking reaction. The results indicated that the fused HLA-B * 2705 protein expression with high efficiency was obtained. The expressed product was more than 50% of the total bacteria protein. The antigenic activity of expressed protein was confirmed by Western blot and antibody blocking reaction. It is concluded that HLA-B * 2705 fusion protein are obtained as basis for the further studies.
Escherichia coli
;
genetics
;
metabolism
;
Genetic Vectors
;
genetics
;
HLA-B27 Antigen
;
classification
;
genetics
;
immunology
;
metabolism
;
Humans
;
Immunoglobulin Heavy Chains
;
genetics
;
immunology
;
metabolism
2.Clinical Features and Prognosis of HLA-B27 Positive and Negative Anterior Uveitis in a Korean Population.
Journal of Korean Medical Science 2009;24(4):722-728
Clinical features and prognosis of HLA-B27 positive anterior uveitis (AU) were assessed compared with HLA-B27 negative AU in a Korean population, based on the medical records of AU patients seen at a university hospital. Twenty-seven HLA-B27 negative, idiopathic AU patients (group I) and 55 HLA-B27 positive AU patients (group II) were studied. HLA-B27 positive group was further divided into 29 with associated systemic disease (seronegative spondyloarthropathy) (group IIA) and 26 without associated systemic disease (group IIB). Significantly more severe anterior chamber inflammation in terms of anterior chamber cells (P=0.006) and hypopyon formation (P=0.034) was observed with higher frequency of AU attacks (P=0.007) in the HLA-B27 positive group than in the HLA-B27 negative group. Systemic/periocular steroids were required in significantly more patients in the HLA-B27 positive group than in the HLA-B27 negative group (P=0.015). However, no significant differences were observed for final ocular and visual outcomes between these two groups. Associated systemic disease made no significant difference in the clinical features and prognosis in the HLA-B27 positive AU patients. In conclusion, despite more severe inflammation and a higher recurrence rate, HLA-B27 positive AU shows similar good final ocular and visual outcomes compared to HLA-B27 negative, idiopathic AU in a Korean population.
Adolescent
;
Adult
;
Aged
;
Alleles
;
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
;
Asian Continental Ancestry Group
;
Case-Control Studies
;
Female
;
HLA-B27 Antigen/genetics/*metabolism
;
Humans
;
Immunosuppressive Agents/therapeutic use
;
Korea
;
Male
;
Middle Aged
;
Prognosis
;
Retrospective Studies
;
Severity of Illness Index
;
Steroids/therapeutic use
;
Uveitis, Anterior/*diagnosis/drug therapy/metabolism
;
Visual Acuity